Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual Sympathetic Blocks for Long COVID Symptoms
NCT05638620Phase 1Completed
- Start
- Jan 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bupivacaine in post-acute sequelae of SARS-CoV-2 infection (PASC). Primary endpoints: Patient-Reported Outcomes Measurement Information System-29 at 1 month, Depression Score at 1 month and 6 more. Started Jan 2023; status: completed.
02
Drugs
bupivacaine
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT05638620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638620.